FDA’s New JAK Safety Restrictions Spell Trouble for AbbVie’s Rinvoq, but to What Extent?
From: FiercePharma By: Angus Liu A recent survey of 100 high-volume U.S. rheumatologists that Piper Sandler conducted with Spherix Global Insights showed that only 14% of patients are getting Rinvoq as prior to TNF inhibitors. And a large number of physicians are avoiding JAKs for patients with high or moderate blood clot risks. Rinvoq […]
‘Erratic’ FDA and Inconsistent Drug Decisions Put Doctors Off New Meds: Survey
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately—and doctors have had enough. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in […]
Specialty Physicians Weigh in with Opinions About the US Food and Drug Administration
![](https://www.spherixglobalinsights.com/wp-content/uploads/2020/12/spherix-logo-400x400-1.png)
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat, Ardelyx’s tenapanor, and the entire JAK inhibitor class EXTON, Pa., July 27, 2021 /PRNewswire/ — In reaction to major market events over the past several months, analysts at Spherix recently captured an increasingly negative sentiment towards the […]
Switching in Rheumatoid Arthritis: Will JAK Inhibitors Peak or Plummet?
By: Maxine Yarnall There’s a reason why Spherix focuses on the new start and switching patient populations within the indications that we cover: it’s where brands have the opportunity to capture share. Whether a patient is initiated on or switched from one advanced systemic therapy to another, there is a window of opportunity for one […]
New Spherix Global Insights’ Patient Audit Highlights Key Differences Between Dermatologists’ and Rheumatologists’ Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands
US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different drivers behind key treatment decisions in patient management EXTON, Pa., April 28, 2021 /PRNewswire/ – The past five or so years have seen a flurry of US biologic approvals for the treatment of psoriasis (PSO), […]
Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains largely virtual, and many practices are unlikely to return to pre-pandemic volumes EXTON, Pa., April 7, 2021 /PRNewswire/ — Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the […]
On the Heels of Recent FDA Approvals, GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) Emerge as Practical and Effective Tools in the Treatment of Lupus Nephritis
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with the drugs EXTON, Pa., March 12, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As many as half of the […]
Tides Continue to Shift as Novartis’ Cosentyx and Eli Lilly’s Taltz Experience Early Success in Non-Radiographic Axial Spondyloarthritis
Managed care decisions will likely have a substantial impact on shaping rheumatologists’ future IL-17 preference, according to Spherix Global Insights EXTON, Pa., February 17, 2021 /PRNewswire/ — Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, have since […]
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry, particularly when it comes to in-person promotion EXTON, Pa., February 12, 2021 /PRNewswire/ — Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global […]
Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla than biologics or JAK inhibitors since the pandemic began in March 2020. Will that growth prevail as pandemic pressures ease? EXTON, Pa., February 10, 2021 /PRNewswire/ — Despite the potential for setbacks brought forth by the COVID-19 […]